Home » Stocks » IMNM

Immunome, Inc. (IMNM)

Stock Price: $17.85 USD 3.17 (21.59%)
Updated Jan 25, 2021 4:00 PM EST - Market closed
After-hours: $17.87 +0.02 (0.11%) Jan 25, 6:52 PM
Market Cap 154.75M
Revenue (ttm) n/a
Net Income (ttm) -11.05M
Shares Out 9.28M
EPS (ttm) -1.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $17.85
Previous Close $14.68
Change ($) 3.17
Change (%) 21.59%
Day's Open 14.94
Day's Range 14.71 - 17.95
Day's Volume 147,273
52-Week Range 9.46 - 17.95


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 month ago

EXTON, Pa.--(BUSINESS WIRE)--Immunome appoints Richard Baron to BOD and Sandra Stoneman as Chief Legal Officer and Corporate Secretary

Business Wire - 2 months ago

EXTON, Pa.--(BUSINESS WIRE)--Immunome Reports Third Quarter 2020 Financial Results and Significant Progress

Business Wire - 3 months ago

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody the...

Benzinga - 3 months ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...

Other stocks mentioned: ESI, SELB, AVO, CCXX, LUNG
Business Wire - 3 months ago

EXTON, Pa.--(BUSINESS WIRE)--Immunome Announces Pricing of Upsized Initial Public Offering

Seeking Alpha - 3 months ago

Immunome Aims For $30 Million U.S. IPO

Market Watch - 4 months ago

Immunome Inc. set terms for its initial public offering, in which the Pennsylvania-based biopharmaceutical company focused on oncology looks to raise up to $32.5 million. The company is offeri...

About IMNM

Immunome, a biotechnology company, discovers, develops, and commercializes highly targeted and native human cancer antibodies against universal cancer antigens. Its RealMAb technology enables the discovery of novel antigens and the cognate native human antibodies that target antigens; and ScreenMab multiplex functional screening technology identifies monoclonal antibodies that have exquisite for tumor neoantigens. The company was founded in 2006 and is based in Exton, Pennsylvania.

IPO Date
Oct 2, 2020
Dr. Purnanand Duddu Sarma
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for Immunome stock is "Strong Buy." The 12-month stock price forecast is 23.00, which is an increase of 28.85% from the latest price.

Price Target
(28.85% upside)
Analyst Consensus: Strong Buy